AI assistant
Moderna, Inc. — Director's Dealing 2025
Jun 9, 2025
30610_dirs_2025-06-09_20b3a466-c4da-4643-b247-142c0ab0d7ed.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-06-06
Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-06 | Common Stock | M | 1139 | — | Acquired | 28034 | Direct |
| 2025-06-06 | Common Stock | F | 551 | $26.12 | Disposed | 27483 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-06 | Restricted Stock Units | $ | M | 1139 | Disposed | Common Stock (1139) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Includes 595 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 30, 2025.
F3: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F4: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. This restricted stock unit award is fully vested as of June 6, 2025.